Login to Your Account

Other News To Note

Wednesday, March 6, 2013
• Dako, of Glostrup, Denmark, part of Agilent Technologies Co., received FDA approval for the addition of Kadcyla (ado-trastuzumab emtansine) to the labeling of two Dako companion diagnostic assays. Kadcyla is marketed by Roche AG unit Genentech Inc., of South San Francisco.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription